• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Roche’s ACE910 gets breakthrough status

Roche’s ACE910 gets breakthrough status

September 4, 2015
CenterWatch Staff

The FDA has granted Roche a breakthrough drug designation for its hemophilia A treatment ACE910 among patients with factor VIII inhibitors.

Investigators for Roche earlier this year had touted long-term follow-up results from ACE910's phase I study, displaying its success in controlling needing episodes among hemophilia patients with or without factor VIII (FVIII) inhibitors. Roughly one in four patients develops the inhibitors, according to the pharmaceutical, which makes the disease especially hard to control.

In a prepared statement, Roche Chief Medical Officer Sandra Horning noted, “People with hemophilia A may require regular and frequent infusions of replacement clotting factor to reduce the risk of dangerous bleeding, and they can develop inhibitors that make replacement ineffective.”

The antibody—an anti-factor IXa/X bi-specific that mimics the function of FVIII, even in the presence of FVIII inhibitors—originally was developed a Chugai, a Roche subsidiary

The FDA has given out dozens of breakthrough drug designations over the past couple of years, pledging to make regulators more readily available to speed through the development process. In particular, the program has helped to alter the structure and timeline of cancer drugs. Roche also has laid out plans to start a phase III study for that treatment among patients with inhibitors before the end of the year, with another late stage study for patients without inhibitors launching next year.

Roche COO Daniel O’Day repeatedly has cited ACE910 as a top prospect for his company, after its lead effort on the PD-L1 checkpoint inhibitor atezolizumab.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing